Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,333 Shares

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total value of $114,521.88. Following the completion of the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,312,716.32. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Septerna Stock Down 1.8%

NASDAQ SEPN opened at $34.00 on Friday. Septerna, Inc. has a 52 week low of $10.62 and a 52 week high of $37.99. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -41.97 and a beta of 2.28. The company has a fifty day moving average of $29.90 and a two-hundred day moving average of $27.61.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. Equities research analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. Wall Street Zen lowered Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Truist Financial boosted their price objective on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus initiated coverage on Septerna in a research report on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, Guggenheim reduced their target price on Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Septerna currently has an average rating of “Moderate Buy” and an average target price of $45.89.

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Group One Trading LLC lifted its stake in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new position in shares of Septerna during the fourth quarter worth $35,000. Russell Investments Group Ltd. acquired a new position in Septerna during the third quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna during the fourth quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Septerna in the fourth quarter valued at $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.